Literature DB >> 18461615

Prevalence of erythrovirus genotypes in the myocardium of patients with dilated cardiomyopathy.

U Kühl1, D Lassner, M Pauschinger, U M Gross, B Seeberg, M Noutsias, W Poller, H-P Schultheiss.   

Abstract

Parvovirus B19 (PVB19) is a member of the human erythrovirus family detected frequently in endomyocardial biopsies from patients with dilated cardiomyopathy. Human erythroviruses cluster into three genotypes 1-3 which share a high degree of homology between major structural proteins and may cause indistinguishable infections clinically and serologically. In human cardiac tissue erythrovirus genotypes other than PVB19 have not yet been reported. Three hundred seventeen consecutive patients with symptomatic dilated cardiomyopathy (median left ventricular ejection fraction: 28.6%, range 5-45%) who underwent endomyocardial biopsy for the elucidation of the etiology, were analyzed using a new consensus PCR assay designed for the detection of the three erythrovirus genotype sequences. Endomyocardial biopsies of 151 (47.6%) patients were erythrovirus-positive. Genotype 1 specific sequences were detected in 43/151 (28.5%) of positive biopsy samples, whereas genotype 2-specific sequences so far considered rare in human disease and not yet been described in human heart tissue was identified in 108/151 (71.5%) of virus-positive endomyocardial biopsies with a preference in patients above 50 years of age. In spite of younger age, systolic left ventricular dysfunction of genotype 1-positive patients was significantly reduced as compared to genotype 2-positive patients (24.4+/-10.4% vs. 31.0+/-9.5%, P=0.0001) at the initial presentation. The data show that two genetically distinct erythrovirus variants with a different age distribution are detectable in endomyocardial biopsies of patients with dilated cardiomyopathy. The erythrovirus genotype 2, not described previously in human heart tissue, is highly prevalent in the heart but the less prevalent genotype 1 is associated with more severe disturbed cardiac function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18461615     DOI: 10.1002/jmv.21187

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  29 in total

1.  Viral epidemiologic shift in inflammatory heart disease: the increasing involvement of parvovirus B19 in the myocardium of pediatric cardiac transplant patients.

Authors:  John P Breinholt; Mousumi Moulik; William J Dreyer; Susan W Denfield; Jeffrey J Kim; John L Jefferies; Joseph W Rossano; Corey M Gates; Sarah K Clunie; Karla R Bowles; Debra L Kearney; Neil E Bowles; Jeffrey A Towbin
Journal:  J Heart Lung Transplant       Date:  2010-04-24       Impact factor: 10.247

2.  Myocardial parvovirus B19 persistence: lack of association with clinicopathologic phenotype in adults with heart failure.

Authors:  Garrick C Stewart; Javier Lopez-Molina; Raju V S R K Gottumukkala; Gregg F Rosner; Mary S Anello; Jonathan L Hecht; Gayle L Winters; Robert F Padera; Kenneth L Baughman; Myra A Lipes
Journal:  Circ Heart Fail       Date:  2010-11-19       Impact factor: 8.790

3.  Pathophysiological mechanisms of parvovirus B19 infection.

Authors:  Michel Noutsias; Sabine Pankuweit; Bernhard Maisch
Journal:  J Clin Microbiol       Date:  2009-07       Impact factor: 5.948

Review 4.  Myocarditis.

Authors:  Sandeep Sagar; Peter P Liu; Leslie T Cooper
Journal:  Lancet       Date:  2011-12-18       Impact factor: 79.321

5.  Biomarkers in inflammatory and noninflammatory cardiomyopathy.

Authors:  Michel Noutsias; Sabine Pankuweit; Bernhard Maisch
Journal:  Herz       Date:  2009-12       Impact factor: 1.443

6.  Diagnostic and prognostic validity of different biomarkers in patients with suspected myocarditis.

Authors:  Christian Ukena; Michael Kindermann; Felix Mahfoud; Jürgen Geisel; Philipp M Lepper; Reinhard Kandolf; Michael Böhm; Ingrid Kindermann
Journal:  Clin Res Cardiol       Date:  2014-04-30       Impact factor: 5.460

Review 7.  Myocarditis: early biopsy allows for tailored regenerative treatment.

Authors:  Uwe Kühl; Heinz-Peter Schultheiss
Journal:  Dtsch Arztebl Int       Date:  2012-05-18       Impact factor: 5.594

Review 8.  The MOGE(S) classification for cardiomyopathies: current status and future outlook.

Authors:  Julian G Westphal; Angelos G Rigopoulos; Constantinos Bakogiannis; Sarah E Ludwig; Sophie Mavrogeni; Boris Bigalke; Torsten Doenst; Matthias Pauschinger; Carsten Tschöpe; P Christian Schulze; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

9.  Molecular phenotypes of human parvovirus B19 in patients with myocarditis.

Authors:  C-Thomas Bock; Anja Düchting; Friederike Utta; Eva Brunner; Bui Tien Sy; Karin Klingel; Florian Lang; Meinrad Gawaz; Stephan B Felix; Reinhard Kandolf
Journal:  World J Cardiol       Date:  2014-04-26

Review 10.  Clinical practice: heart failure in children. Part I: clinical evaluation, diagnostic testing, and initial medical management.

Authors:  Paul F Kantor; Luc L Mertens
Journal:  Eur J Pediatr       Date:  2009-08-26       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.